The second arm of the trial was the placebo arm (n = 367). The final primary endpoints of SUMMIT were a combination of ...

Both the nasal and IV forms of bumetanide had a variability in absorption of 27%, suggesting a more stable route of dosing ...

We know that exercise is good for our hearts and overall health. But is that true for people living with heart failure? And ...

Twin sisters living with heart failure are calling for an end to what they say is a postcode lottery when it comes to ...

Sitting for over 10 hours or more a day is significantly linked to future heart failure and cardiovascular death risk, a new ...

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among ...

Valuable data can successfully be collected with the noninvasive wearable, which is worn on the sternum, report investigators ...

The combination of sacubitril and valsartan reduces the cardiotoxicity related to anthracycline chemotherapy drugs, according ...

A new study by researchers at Intermountain Health in Salt Lake City finds that 40 percent of newly diagnosed heart failure patients also have atrial fibrillation – a combination of cardiac disorders ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Heart failure sounds scary - because it is. But here's the thing: millions of Americans are walking around right now with a ...

The existing oral and intravenous forms of bumetanide are commonly prescribed for people with heart failure because they ease tissue swelling, a common cause of symptoms for people with heart failure.